Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Aptevo Therapeutics Inc. (NASDAQ:APVO) saw a significant drop in short interest in December. As of December 31st, there was short interest totalling 19,000 shares, a drop of 92.1% from the December 15th total of 241,700 shares. Based on an average daily trading volume, of 325,400 shares, the short-interest ratio is presently 0.1 days. Approximately 1.3% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on APVO shares. StockNews.com initiated coverage on Aptevo Therapeutics in a report on Monday, December 9th. They set a “sell” rating on the stock. Roth Mkm dropped their target price on Aptevo Therapeutics from $20,535.00 to $10,952.00 and set a “buy” rating for the company in a report on Monday, September 23rd.

Aptevo Therapeutics Trading Down 5.0 %

Shares of Aptevo Therapeutics stock opened at $4.55 on Tuesday. Aptevo Therapeutics has a 1 year low of $3.65 and a 1 year high of $399.60. The company has a 50-day moving average of $161.91 and a 200 day moving average of $329.93.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC bought a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.